" class="no-js "lang="en-US"> XtalPi Archives - Medtech Alert
Friday, September 26, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques

Science and technology company Merck and XtalPi, a pioneering pharmaceutical technology company powered by artificial […]

XtalPi and EDDC Collaborate in AI-empowered Drug Discovery Program for Non-Small Cell Lung Cancer

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, has announced […]

Antengene and XtalPi Announce AI-Driven R&D Collaboration

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more